HS
CCCC icon

HighVista Strategies’s C4 Therapeutics CCCC Stock Holding History

HighVista Strategies’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.3M Buy
+1,348,136
New +$4.61M 1.44% 19
2022
Q2 		– Sell
-34,760
Closed -$843K – 111
2022
Q1 		$843K Buy
34,760
+3,267
+10% +$79.3K 0.54% 53
2021
Q4 		$1.01M Buy
31,493
+2,152
+7% +$85.1K 0.81% 46
2021
Q3 		$1.31M Buy
29,341
+7,612
+35% +$326K 0.87% 28
2021
Q2 		$822K Buy
21,729
+4,142
+24% +$148K 0.58% 36
2021
Q1 		$651K Buy
+17,587
New +$700K 0.48% 49

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HighVista Strategies's CCCC Position: Q2 2026 in Review

HighVista Strategies opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 1,348,136 shares worth $6.3M. The stake represents 1.44% of the portfolio and ranks #19 among its holdings. This is a return to the name: HighVista Strategies previously reported a position in CCCC as recently as Q1 2022.

HighVista Strategies first reported a position in CCCC in Q1 2021 and has held it in 6 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • HighVista Strategies held 1,348,136 shares of C4 Therapeutics worth $6.3M as of Q2 2026.
  • C4 Therapeutics was a new HighVista Strategies position in Q2 2026.
  • C4 Therapeutics made up 1.44% of HighVista Strategies's portfolio in Q2 2026, its #19 holding.
  • HighVista Strategies first reported a position in C4 Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.